Indirubin-3'-monoxime

Indirubin-3'-monoxime is an inhibitor of CDK and CDK1 and related targets used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. It is especially relevant in cancer, cell cycle, and cell signaling models, where defined compound exposure can be linked to inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses.

By inhibiting CDK and CDK1 and related targets, Indirubin-3'-monoxime can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CDK and CDK1 and related targets
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Indirubin-3'-monoxime is appropriate when a defined chemical perturbant is needed to connect CDK and CDK1 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.